VANCOUVER, BC, March 31, 2021 /CNW/ - Sirona Biochem Corp.
(TSXV: SBM) (FSE: ZSB) (US-OTC:
SRBCF) ("Sirona") is pleased to announce that the
second clinical trial of the active ingredient, TFC-1067, has been
completed with excellent results.
The trial, which concluded on January
22nd, 2021, was managed by Dermscan (a division
of Eurofins), a global leader in cosmetic clinical trials. The
study's endpoint was to determine the compound's ability to
selectively reduce areas of hyperpigmentation and dark spots of the
skin while not creating a "halo" around the spot, which is a known
side effect of other treatments. Multiple parameters were measured
including the added effects of the higher concentration of TFC-1067
and a boosted formulation.
Results of the trial included:
- A significant decrease in spot intensity
- A significant decrease in spot size
- A significant decrease in dark spots versus surrounding skin
tone
Optimal results were obtained with the higher concentration and
improved formulation:
- 100% of participants agreed their complexion was
illuminated
- 100% of participants agreed their complexion was brighter
- 100% of participants agreed their skin was more even in
tone
- 100% of participants agreed the product blurred
imperfections
- 100% of participants agreed the product prevented new dark
spots from occurring
- 100% of participants agreed the spot size and mark was
reduced
- 100% of participants agreed the intensity of dark spots was
reduced
- 100% of participants would purchase the product
Due to contractual obligations, further disclosures will not be
made at this time.
The Company also reports an increase in international interest
in the project since the commercial launch of TFC-1067.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.